Navigation Links
Superior Patient Clinical Outcomes Confirms DaVita's Leadership Position on Quality Dialysis Care
Date:7/7/2008

Outcomes data confirms that the risk of mortality faced by patients at

DaVita facilities may be 8% lower than the national average

EL SEGUNDO, Calif., July 7 /PRNewswire-FirstCall/ -- DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney failure and disease (CKD), significantly exceeds national averages with regard to patient quality, as validated by both the Clinical Performance Measures Report published in 2006 by the Centers for Medicare and Medicaid Services (CMS), and the December 2007 Fistula First Vascular Access Improvement Initiative. This achievement is notable among the nation's kidney care community because DaVita(R) serves more than 1-in-4 dialysis patients in America.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

"At DaVita, our highest priority is the health and well-being of the more than 100,000 patients cared for by our professional partners and teammates," said Kent Thiry, CEO of DaVita. "We're pleased that this commitment has once again been validated by the findings from CMS."

Research studies show that patients who meet all four of the CMS Clinical Performance Measures (CPM) and the National Kidney Foundation's (NKF) Kidney Disease Outcomes Quality Initiative (KDOQI) achieve the lowest mortality.(a,b) Outcomes data confirms that the risk of mortality faced by patients dialyzed at DaVita facilities may be as much as 8% lower than the national average.

DaVita consistently surpasses national averages for CMS CPM and KDOQI outcomes. Most recently, DaVita outperformed the national averages by as much as 44% on four key clinical performance outcomes. A recent study that compared the mortality trends for the major dialysis providers found that DaVita had a significant improvement in survival compared to non-chain facilities.(c)


'/>"/>

SOURCE DaVita Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Increasing Sales Productivity Through Superior Sales Force Performance Management
2. By adding graphene, researchers create superior polymer
3. Flurizans Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimers Disease is Superior to That of Aricept
4. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
5. Study Reaffirms Superiority of Trofile(TM) Assay
6. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
7. Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007
8. New Aptivus(R) (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
9. TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment
10. Derma Sciences MEDIHONEY(TM) Helps to Save Patients Limb
11. A Perfect Storm Threatens Patient Access to Specialty Medical Care

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... The Scientist, a leading scient...hotometrics’ Evolve “Intelligent&rdquo...s “Top 10 Innovations of 2009. , ...lve ™ EMCCD camera from Photometrics ®...CCD and EMCCD cameras for the life sciences, was r...
(Date:12/1/2009)... , NEW YORK, Dec. 1 Report...port is available in its catalogue: ,, Chromi...rtlinker.com/p0164494/Chromium---Global-Market-Tre...rimarily influenced by stainless steel, while grow... is also important for growth of chromium metal. E...
(Date:12/1/2009)... , CAMBRIDGE, Mass., Dec. 1 /PRNewswire/ ...gy industry and to promote its potential, a group ...on of the Synthetic Biology Industry Association (... goal of the association is to provide a forum for...he new industry, address its opportunities and its...
(Date:12/1/2009)... , SPRINGFIELD, Ill., Dec. 1 ...ud to announce that it was recently awarded two st...event on Nov. 13 in New York City. The CLIO Health...ovation in the healthcare advertising industry and...rld,s most recognized awards competitions for adve...
Breaking Biology Technology:The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2
...oy, N.Y. - A new biochip technology could eliminat...dustries, and drastically curtail its use in the d...w findings from a team of researchers at Rensselae...nia at Berkeley, and Solidus Biosciences Inc. , ...in the online Early Edition of the Proceedings of ...
...VER, Dec. 17 /PRNewswire-FirstCall/ - Angiotech Ph...lobal specialty pharmaceutical and,medical device ...10(k),application to the U.S. Food and Drug Admini...5-Fluorouracil-coated (5-FU) Central Venous,Cathet...sion of a 510(k) application to,the FDA for our 5-...
...GTON, Mass., Dec. 17 LeMaitre Vascular,Inc. (Nasd...ussell D. Hays,has been appointed to its Board of ...s will serve as a Class II director, standing for ...,s shareholders, and will also serve,as Chair of t...ommittee and,as a member of its Audit Committee., ...
Other Biology Technology:Biochip mimics the body to reveal toxicity of industrial compounds 2Biochip mimics the body to reveal toxicity of industrial compounds 3Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 2Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 3Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 4Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 5LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors 2
(Date:12/2/2009)...pei Suzuki Diabetes Foundation is pleased to annou...nald F. Steiner, MD, A. N. Pritzker Distinguished ...e and Biochemistry and Molecular Biology, The Univ...ated in 2008 to commemorate the 15th anniversary o...those who have enlightened researchers in the fiel...
(Date:12/2/2009)..., REDWOOD CITY, Calif., Dec. 2 D...ity and authentication solutions, today announced ... DigitalPersona biometric fingerprint technology o...na U.are.U® 4500HD offering allows point-of-s...fy users so that specific transactions can be link...
(Date:12/2/2009)...e-walled nanotubescylinders of carbon about a nano...tial applications such as ultrastrong fibers, elec...rage components for fuel cells. Thanks to a new de... of Standards and Technology (NIST) and five partn... detection and destruction of an aggressive form o...
Breaking Biology News(10 mins):DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Combining nanotubes and antibodies for breast cancer 'search and destroy' missions 2Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 1Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 2Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 3Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 4Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 5Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 6Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 7Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting 5855 8Consumer Reports Health 3A Americans With Heartburn Paying Too Much Green For Nexiums Purple Pill 5853 1Consumer Reports Health 3A Americans With Heartburn Paying Too Much Green For Nexiums Purple Pill 5853 2Consumer Reports Health 3A Americans With Heartburn Paying Too Much Green For Nexiums Purple Pill 5853 3Xanodyne Raises 2450 Million in Equity Financing to Support Emerging Product Portfolio 5851 1Xanodyne Raises 2450 Million in Equity Financing to Support Emerging Product Portfolio 5851 2
...d. (August 11, 2008) − In a study on fetal a...the damage that alcohol causes to cells in a key a...potassium channels and preventing the acidic envir...portion of the brain that is responsible for balan...able to injury from alcohol during development. , ...
...228 women has revealed genetic variants responsibl...rosophila melanogaster, research published today i...s natural variation in the human LAMA5 gene as a k...obesity and related health problems continues to i...ing devoted to identify genetic mechanisms that co...
...A. Geisinger Medical Center,s microbiology lab is...rument that improves the quality and efficiency of...ng demand for lab services. , Geisinger,s lab ha...k-Away Specimen Processor (WASP), which hit the ma...botsdubbed Tarzan and Jane by the manufacturercan ...
Other Biology News:Researchers block damage to fetal brain following maternal alcohol consumption 2Geisinger piloting innovative laboratory specimen processing instrument 2
...l)-Val-phenylalaninal 2-Naphthoyl-VF-CHO White l...ER INERT GAS. A cell-permeable, reversible inhibit... release of Aβ x-40 (ED 50 = 2.6 μM) and...s stably transfected with the Amyloid Precursor Pr...
Afe I from New England Biolabs
Mouse Anti-Human Troponin I Monoclonal Antibody, Unconjugated, Clone 12F10 from ABR-Affinity BioReagents
Bcl I (HC) from Promega
Biology Products: